US LNG exports surge but will buyers in China turn up?
CytoMed Therapeutics Ltd (NASDAQ:GDTC) announced that all proposals presented at its annual shareholders meeting held on June 26 were approved, according to a statement released in a recent SEC filing.
At the meeting, shareholders representing approximately 66.06% of the company’s 11,540,000 outstanding ordinary shares participated by proxy, meeting the quorum requirements.
Key proposals approved included the adoption of the directors’ statement and audited financial statements for the year ended December 31, 2024. The re-election of Dr. Zeng Jieming, Mr. Mark Leong Kei Wei, and Prof. Loh Yuin Han as directors was also confirmed, with each receiving more than 99.9% of votes cast in favor.
Shareholders ratified the appointments of WWC, P.C. and KE Trust PAC as independent registered public accounting firms for the financial year ending December 31, 2025. The board was authorized to fix the auditors’ remuneration at its discretion.
The meeting approved the payment of directors’ fees totaling $70,000 for the 2025 financial year.
Resolutions also authorized the board to issue new ordinary shares and related instruments in accordance with Singapore law and Nasdaq listing rules, subject to shareholder approval at future meetings. A special resolution was passed to amend the company’s constitution, removing the requirement to publish notices of general meetings in the daily press.
All voting results, as detailed in the filing, showed strong support for each proposal, with percentages in favor generally exceeding 99% of votes cast.
This information is based on a press release statement included in CytoMed Therapeutics Ltd’s recent SEC filing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.